Smith & Nephew PLC (SNN)
Stock Price Chart
Key Info
| Market Cap | 17.95B |
| Revenue (ttm) | 4.69B |
| Net Income (ttm) | 600.00M |
| Shares Out | 437.80M |
| EPS (ttm) | 0.89 |
| PE Ratio | 46.15 |
| Forward PE | 30.49 |
| Dividend | $0.75 |
| Dividend Yield | 1.83% |
Stock Quote
| Trading Day | Aug 14, 2020 |
| Last Price | $41.07 |
| Previous Close | $41.99 |
| Change ($) | -0.92 |
| Change (%) | -2.19% |
| Day's Open | 41.41 |
| Day's Range | 40.94 - 41.47 |
| Day's Volume | 167,640 |
| 52-Week Range | 26.07 - 52.26 |
More Stats
| Market Cap | 17.95B |
| Enterprise Value | 19.72B |
| Earnings Date (est) | n/a |
| Ex-Dividend Date | Apr 2, 2020 |
| Shares Outstanding | 437.80M |
| Float | 433.03M |
| EPS (basic) | 1.372 |
| EPS (diluted) | 0.89 |
| FCF / Share | 2.17 |
| Dividend | $0.75 |
| Dividend Yield | 1.83% |
| Earnings Yield | 2.17% |
| FCF Yield | 5.36% |
| Payout Ratio | n/a |
| Shares Short | 636,206 |
| Short Ratio | 1.32 |
| Short % of Float | n/a |
| Beta | 0.24 |
| PE Ratio | 46.15 |
| Forward PE | 30.49 |
| P/FCF Ratio | 18.66 |
| PS Ratio | 3.83 |
| PB Ratio | 3.72 |
| Revenue | 4.69B |
| Operating Income | 815.00M |
| Net Income | 600.00M |
| Free Cash Flow | 962.00M |
| Net Cash | -1.77B |
| Net Cash / Share | -4.05 |
| Gross Margin | 81.21% |
| Operating Margin | 17.38% |
| Profit Margin | 11.70% |
| FCF Margin | 20.52% |
| ROA | 3.59% |
| ROE | 7.89% |
| ROIC | n/a |
Analyst Summary
Analyst Consensus: Overweight
Financial Performance
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5,138 | 4,904 | 4,765 | 4,669 | 4,634 | 4,617 | 4,351 | 4,137 | 4,270 | 3,962 |
| Revenue Growth | 4.77% | 2.92% | 2.06% | 0.76% | 0.37% | 6.11% | 5.17% | -3.11% | 7.77% | - |
| Gross Profit | 3,800 | 3,606 | 3,517 | 3,397 | 3,491 | 3,455 | 3,251 | 3,067 | 3,130 | 2,931 |
| Operating Income | 815 | 863 | 934 | 801 | 628 | 749 | 810 | 846 | 862 | 920 |
| Net Income | 600 | 663 | 767 | 784 | 410 | 501 | 556 | 721 | 575 | 615 |
| Shares Outstanding | 888 | 891 | 904 | 915 | 951 | 918 | 964 | 951 | 951 | 951 |
| Earnings Per Share | 1.37 | 1.51 | 1.75 | 1.76 | 0.91 | 1.11 | 1.23 | 1.60 | 1.28 | 1.38 |
| EPS Growth | -9.64% | -13.68% | -0.11% | 92.54% | -18.13% | -9.28% | -23.25% | 24.61% | -7.23% | - |
| Dividend Per Share | 0.73 | 0.72 | 0.61 | 0.63 | 0.60 | 1.05 | 1.30 | 1.02 | 0.79 | 0.72 |
| Dividend Growth | 0.55% | 19.47% | -3.19% | 4.68% | -43.05% | -19.23% | 27.45% | 29.11% | 9.72% | - |
| Operating Cash Flow | 1,370 | 1,108 | 1,273 | 1,035 | 1,203 | 961 | 1,138 | 1,184 | 1,135 | 1,111 |
| Capital Expenditures | -408 | -347 | -376 | -392 | -358 | -355 | -340 | -265 | -321 | -307 |
| Free Cash Flow | 962 | 761 | 897 | 643 | 845 | 606 | 798 | 919 | 814 | 804 |
| Cash & Equivalents | 277 | 365 | 169 | 100 | 120 | 93.00 | 137 | 178 | 184 | 207 |
| Total Debt | 2,047 | 1,465 | 1,450 | 1,650 | 1,480 | 1,705 | 391 | 468 | 322 | 699 |
| Net Cash / Debt | -1,770 | -1,100 | -1,281 | -1,550 | -1,360 | -1,612 | -254 | -290 | -138 | -492 |
| Assets | 9,299 | 8,059 | 7,866 | 7,344 | 7,167 | 7,306 | 5,819 | 5,642 | 4,747 | 4,733 |
| Liabilities | 4,158 | 3,185 | 3,222 | 3,386 | 3,201 | 3,266 | 1,772 | 1,758 | 1,560 | 1,960 |
| Book Value | 5,141 | 4,874 | 4,644 | 3,958 | 3,966 | 4,040 | 4,047 | 3,884 | 3,187 | 2,773 |
Company Profile
Company Details
| Full Name | Smith & Nephew PLC |
| Country | United Kingdom |
| Employees | 17,500 |
| CEO | Roland D. Diggelmann |
Stock Information
| Ticker Symbol | SNN |
| Stock Exchange | New York Stock Exchange |
| Sector | Healthcare |
| Industry | Medical Devices |
| Unique Identifier | NYSE: SNN |
| IPO Date | November 16, 1999 |
Description
Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers knee implant products for specialized knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.